Building on our previous findings demonstrating the potent antiproliferative activity of BTHP against breast cancer cells via targeting vascular endothelial growth factor receptor-2, our current study investigated its therapeutic potential in an EAC-induced murine model. Here, KDR is linked to breast carcinoma.